Current evidence of COVID-19 vaccination-related cardiovascular events

Khiali, Sajad; Rezagholizadeh, Afra; Behzad, Hossein; Baghi, Hossein Bannazadeh; Entezari‐Maleki, Taher

doi:10.1080/00325481.2022.2161249

Cited by 5 publications

(2 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, we did not find any association between systolic and diastolic pressure and post-vaccination adverse events. Although this finding was rather expected because all study participants were not affected by arterial hypertension, however this a significant result because blood pressure levels have been associated with lower Ab titres following as well as COVID-19 vaccination was reported to affect blood pressure control [37].…”

Section: Discussionmentioning

confidence: 85%

Evaluation of Adverse Effects after the Second Dose of BNT162b2 Mrna Vaccination for COVID-19: A Survey-based Analysis among Italian Healthcare Workers

Ferrazza,

Nucera,

Longo

et al. 2023

TOPHJ

View full text Add to dashboard Cite

Backgrounds and Aims: Since the start of the SARS-CoV-2 pandemic, healthcare workers have been at elevated risk of contracting COVID-19. Although COVID-19 vaccines have contributed to the eradication of, or substantial decreases in, the incidence of lethal diseases, the major determinant of COVID-19 vaccine hesitancy is a fear of associated adverse effects. Here, we performed a survey assessing the reactogenicity and safety of BNT162b2 in a real-world setting. Methods: Data were collected from March 1 and June 14, 2021. A total of 206 hospital employees undergoing BNT162b2 mRNA vaccination completed the survey. These hospital workers received a questionnaire to collect the common and uncommon adverse effects developing 2–6 days after the second dose of the Pfizer-BioNTech vaccine. Results: After the second dose, female sex was found to be associated with a higher risk of vaccine-related severe systemic adverse effects than male sex (odds ratio [OR] 3.116, 95% CI 2.365–7.113). We also observed that the anti-SARS-CoV-2 receptor-binding domain titer, determined on the day when the second dose of the Pfizer-BioNTech vaccine was administered, was significantly higher in participants with severe systemic effects than those without such effects (OR 1.017, 95% CI 1.001–1.034). Conclusion: Our study suggested that healthy female healthcare workers had a three-fold higher risk than healthy male healthcare workers of developing severe adverse effects after the second dose of the Pfizer-BioNTech vaccine. Further research is warranted to determine whether a high anti-SARS-CoV-2 RBD titer determined at the time of the second vaccination might indicate a disproportionate inflammatory systemic reaction leading to severe adverse effects. Our findings might contribute to a decrease in the disappearance of COVID-19 vaccine hesitancy.

show abstract

Section: Discussionmentioning

confidence: 85%

Evaluation of Adverse Effects after the Second Dose of BNT162b2 Mrna Vaccination for COVID-19: A Survey-based Analysis among Italian Healthcare Workers

Ferrazza,

Nucera,

Longo

et al. 2023

TOPHJ

View full text Add to dashboard Cite

show abstract

“…Understanding these autoimmune responses is crucial for managing potential adverse effects post-vaccination. A comprehensive review of cardiovascular complications following COVID-19 vaccination sheds light on the spectrum of cardiac events post-vaccination and the need for careful assessment of underlying cardiovascular disease and risk factors [71,72]. Current evidence on SARS-CoV-2 mRNA vaccines indicates an increased risk of pericarditis and cardiac events, though these remain relatively rare [73].…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular Disorders and Pregnancy Complications Post-COVID-19: Investigating the Potential Role of Vaccination

Sadiq,

Al-Amran

2023

Preprint

View full text Add to dashboard Cite

In a detailed study of 420 pregnant women in the last trimester from southern and central Iraq, aged 15 to 36 years, the impact of COVID-19 vaccinations on cardiovascular risk factors was assessed. The study's cohort displayed diverse vaccination statuses, with 50% receiving two vaccine doses and 10% receiving one dose, involving brands like Pfizer and Sinopharm. The findings indicated a notable distinction in cardiovascular responses between vaccinated and unvaccinated pregnant women. Vaccination seemed to reduce certain cardiovascular risks during pregnancy in the COVID-19 era. However, the extent of risk mitigation varied based on the number of vaccine doses and the vaccine type. In summary, the research suggests a potential protective effect of full COVID-19 vaccination against cardiovascular risks in pregnancy. These results highlight the need for further investigations into the specific effects of different COVID-19 vaccines on cardiovascular health in pregnancy.

show abstract